Clinical Trial Update: Extended Treatment With PEG-Intron® and Rebetol® in Patients With Genotype 1 Chronic Hepatitis C and Slow Virologic Response (Study P03685) [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating extended treatment with PEG-Intron and Rebetol in genotype 1 chronic hepatitis C patients with slow virologic response has completed,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• PEG Intron (pegylated interferon alfa-2b)
• Rebetol (ribavirin)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Hepatitis C, Chronic | Phase 3 | Status: COMPLETED | Results posted: 2009-07-08